Ascendiant Capital raises Lucid Diagnostics target to $9.50
Ascendiant Capital raised its Lucid Diagnostics price target to $9.50 per share from $9.25.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.